Chandrikha Chandrasekharan, MBBS
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Clinical Associate Professor, Cancer Medicine, GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2007 | Government Kilpauk Medical College, Chennai, IN, Bachelor of Medicine, Bachelor of Surgery |
Postgraduate Training
| 2015-2016 | Advanced GI Medical Oncology, Mayo Clinic, Rochester, Minnesota |
| 2013-2015 | Medical Oncology Fellow, Louisiana State University, Shreveport, Louisiana |
| 2012-2013 | Hospice and Palliative Medicine Fellow, Mayo Clinic, Rochester, Minnesota |
| 2009-2012 | Internal Medicine Resident, University Of Florida College of Medicine, Jacksonville, Florida |
Licenses & Certifications
| 2024 | Texas Medical Board |
| 2016 | Hospice and Palliative Medicine Board Certification |
| 2016 | Iowa State Medical License |
| 2015 | Medical Oncology Board Certification |
| 2013 | Louisiana State Medical License |
| 2012 | Internal Medicine Board Certification |
| 2012 | Minnesota State Medical License |
| null | ECFMG Certified |
| null | Certified Medical Professional - Tamil Nadu (India) Medical Council |
Experience & Service
Faculty Academic Appointments
Adjunct Clinical Associate Professor, University of Iowa, Iowa City, Iowa, 2024 - 2025
Clinical Associate Professor, University of Iowa, Iowa City, Iowa, 2022 - 2024
Principal Investigator, Alliance for Clinical Trails in Oncology, University of Iowa, Iowa City, Iowa, 2022 - 2024
Multidisciplinary Group Co-Leader, University of Iowa, Iowa City, Iowa, 2022 - 2024
Principal Investigator, Alliance for Clinical Trails in Oncology, University of Iowa, Iowa City, Iowa, 2018 - 2022
Co-Principal Investigator, Alliance for Clinical Trails in Oncology, University of Iowa, Iowa City, Iowa, 2018 - 2022
Section Chief, University of Iowa, Iowa City, Iowa, 2018 - 2022
Clinical Assistant Professor, University of Iowa, Iowa City, Iowa, 2017 - 2022
Intramural Institutional Committee Activities
Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Extramural Institutional Committee Activities
Co-Chair, NANETS Annual Symposium Committee, North American Neuroendocrine Tumor Society, 2025 - Present
Chair, Women in NETS Special Interest Group, North American Neuroendocrine Tumor Society, 2024 - Present
Chair, NANETS Continuing Education Committee, North American Neuroendocrine Tumor Society, 2024 - 2025
Co-Chair, NANETS Continuing Education Committee, North American Neuroendocrine Tumor Society, 2023 - 2024
Volunteer, Virtual Tumor Board, Binaytara Foundation (NPO), 2021 - Present
Member, Institutional Review Board, University of Iowa, 2021 - 2024
Member, Trial Resources Evaluation Committee, University of Iowa, 2021 - 2024
Co-Chair, Women in Neuroendocrine Tumors, North American Neuroendocrine Tumor Society, 2021 - 2023
Member, Fellowship Evaluation and Selection Committee, University of Iowa, 2021 - 2023
Member, Mentorship Committee, North American Neuroendocrine Tumor Society, 2020 - 2022
Member, NANETS Annual Symposium Committee, North American Neuroendocrine Tumor Society, 2019 - 2021
Honors & Awards
| 2023 - 2024 | Faculty of the Year Award, Division of Medical Oncology and Hematology, University of Iowa |
| 2022 | Patients' Choice Award for Patient Excellence, Top 10% Nationally, University of Iowa |
| 2019 | Mark Walcott Award for Clinical Excellence in Care Nominee, Iowa City VA Health Care System |
| 2001 - 2007 | Government of India Merit Scholarship, Top 1% Students Across India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Neuroendocrine Tumors-Recent Updates and Future Perspectives. Invited. Feist Weiller Cancer Center Grand Rounds. Shreveport, Louisiana, US.
- 2024. Tumor Thrombosis-Diagnostic Dilemma. Invited. Clinical Pathology Conference Grand Rounds. Iowa City, Iowa, US.
- 2021. Advances in the Field of Neuroendocrine Tumors. Invited. Gunderson Cancer Center Grand Rounds, US.
- 2021. Neuroendocrine Tumors – Past, Present and the Future. Invited. Internal Medicine Grand Rounds. Iowa City, Iowa, US.
- 2021. CDK 4/6 and MEK targeted therapy in pancreatic neuroendocrine tumors. Invited. Holden Cancer Center Grand Rounds, US.
Regional Presentations
- 2025. Guidelines vs. Reality - Are the current ki67 cutoffs appropriate for treatment decisions. Invited. 2025 NANETS Symposium. Austin, Texas, US.
- 2025. Navigating the Expanding NET Treatment Arsenal. Invited. CME Plexus, Louisiana, US.
- 2025. Genetics, risk factors, and survivorship beyond diagnosis. Invited. Know Your NETs Virtual Patient and Caregiver Conference, US.
- 2025. Updates in Neuroendocrine Tumors. Invited. Highlights in GI Oncology. Orlando, Florida, US.
- 2024. Updates in Neuroendocrine Tumors. Invited. Society of Abdominal Radiology Webinar, US.
- 2024. Management of Grade 3 Well-Differentiated Neuroendocrine Tumors. Invited. NANETS Regional NET Symposium. Minneapolis, Minnesota, US.
- 2024. Novel Therapeutics and Diagnostics in NETs. Invited. NANETS/ENETS Webinar, US.
- 2023. Colorectal Cancer Ground Shot - Work in Progress. Invited. Annual Adolescent and Young Adult Cancer Symposium. Iowa City, Iowa, US.
- 2023. Molecular Tumor Board Panelist/Case Presentation. Invited. Precision Oncology Summit, US.
- 2022. Review of Current Clinical Trials in Neuroendocrine Tumors. Invited. Society of Nuclear Medicine and Molecular Imaging Fall Therapeutic Conference, US.
- 2022. Updates in GI Oncology- Pancreaticobiliary and Upper GI Cancers. Invited, US.
- 2022. Pancreatic Adenocarcinoma-Principles of Medical Management. Invited. Annual Scofield Nursing Conference, US.
- 2022. Cancer Care Disparities-Training the Next Generation. Invited. Summit on Cancer Disparities, US.
- 2021. Management of Progressive Grade 3 NET. Invited. NANETS Eastern Regional Conference, US.
- 2020. Treatment Sequencing for NETs - Where Does PRRT Fit In. Invited. Know Your NETS Patient and Caregiver Conference, US.
- 2019. NETS and Bolts: What’s in the NET Treatment Toolbox and How to Sequence Treatments. Invited. Chicago NET Patient and Caregiver Education Conference, US.
- 2019. Management of Anemia and Other Common Hematology Oncology Problems for PCP. Invited, US.
- 2017. Role of Targeted Therapies in Neuroendocrine Tumors. Invited. Iowa Neuroendocrine Cancer Patient Conference, US.
National Presentations
- 2023. Highlights of the day-Gastroesophageal, Pancreatic and Hepatobiliary Cancers. Invited. 2023 ASCO Annual Meeting, US.
- 2022. Sequencing systemic therapies with PRRT. Invited. 2022 NANETS Annual Symposium, US.
Grant & Contract Support
| Date: | 2023 - 2026 |
| Title: | A randomized, open-label, Phase II, dose/schedule optimization study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated colorectal cancers |
| Funding Source: | NuCana |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | A Phase 1b/2, dose-escalation, randomized, multicenter study of maintenance Ivaltinostat plus or Capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first line mFOLFIRINOX-CG-745-2-08 |
| Funding Source: | CG Pharmaceuticals |
| Role: | Site PI |
| Date: | 2023 - 2025 |
| Title: | First in human phase 1/2 trial of ELI-002 7P immunotherapy as treatment for subjects with KRAS/NRAS viral oncogene homolog mutated solid tumors ELI-002-20 |
| Funding Source: | Elicio Therapeutics |
| Role: | Site PI |
| Date: | 2023 - 2024 |
| Title: | A Phase 1, open label multi-center dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of PF-07284892 (ARRY- 558) as a single agent and in combination therapy-C4481001 |
| Funding Source: | Pfizer |
| Role: | Site PI |
| Date: | 2023 - 2024 |
| Title: | Elucidating the role of 8-hydroxy-2′-deoxyguanosine modification in thrombogenesis in colorectal cancer |
| Funding Source: | Institutional Pilot |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | A phase 1, open-label, dose escalation and expansion study of PF-07265028 as a single agent and in combination with sasanlimab evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumors activity of PF-07265028 in participants C4731001 |
| Funding Source: | Pfizer |
| Role: | Site PI |
| Date: | 2022 - 2024 |
| Title: | Testing the combination of high dose Ascorbate and Avasopasem, a SOD mimetic along with standard of care preoperative chemotherapy and radiation in gastroesophageal cancers |
| Funding Source: | DeGregorio Family Foundation |
| Role: | Co-PI |
| Date: | 2022 |
| Title: | Clinical Core C |
| Funding Source: | NIH NCI Neuroendocrine SPORE |
| Role: | Co-Director |
| Date: | 2021 - 2024 |
| Title: | A phase 2 study to evaluate the efficacy and safety of MK-6482 monotherapy in patients with advanced pheochromocytoma/paraganglioma and pancreatic neuroendocrine tumors MK-6482-15 |
| Funding Source: | Merck Sharp & Dohme LLC |
| Role: | Site PI |
| Date: | 2021 - 2024 |
| Title: | A multicenter, open-label, phase 1 study evaluating the tolerability of HMPL-306 in patients with locally Advanced or metastatic solid tumors with IDH mutation-GLOB2 |
| Funding Source: | Hutchison Medi Pharma Limited |
| Role: | Site PI |
| Date: | 2021 - 2024 |
| Title: | Comparative Effectiveness Research- Neuroendocrine Tumors |
| Funding Source: | PCORI |
| Role: | Clinical Lead |
| Date: | 2021 - 2023 |
| Title: | An open-label phase 1b/II study of Surufatinib in combination with Tislelizumab in subjects with advanced Solid tumors-GLOB 1 |
| Funding Source: | Hutchison Medi Pharma Limited |
| Role: | Site PI |
| Date: | 2021 - 2023 |
| Title: | SGN-TUC022 Mountaineer-02, A randomized double blind, placebo -controlled active comparator Phase 2/3 study of Tucatinib in combination with Trastuzumab, Ramucirumab and Paclitaxel in locally Advanced unresectable or advanced Her2 amplified gastroesophageal junction or gastric adenocarcinoma |
| Funding Source: | Seagen Inc |
| Role: | Site PI |
| Date: | 2020 - 2024 |
| Title: | Immunotherapy combined with Yttrium-90 radioembolization in treating colorectal cancer with liver metastases |
| Funding Source: | Biocompatibles |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | A phase 2 randomized, double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab In patients with unresectable, advanced esophageal squamous cell carcinoma Yo421337 |
| Funding Source: | Genentech |
| Role: | Site PI |
| Date: | 2019 - 2025 |
| Title: | RR3: Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC) |
| Funding Source: | RenovoRx |
| Role: | Site PI |
| Date: | 2019 - 2024 |
| Title: | Alpha Particle emitter peptide receptor radionucleotide therapy for NET |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | A Phase 1/1b study of ASP2074 in participants with Metastatic or Locally Advanced solid tumors 2074=CL-0101 |
| Funding Source: | Astellas Pharmaceuticals |
| Role: | Site PI |
| Date: | 2019 - 2020 |
| Title: | A phase II study of combination of Abemaciclib and Pembrolizumab in locally advanced unresectable or Metastatic gastroesophageal adenocarcinoma BTCRC -GI 18-149 |
| Funding Source: | Merck |
| Role: | Site PI |
| Date: | 2019 - 2020 |
| Title: | Circulating tumor cell capture in neuroendocrine tumors using CapioCyte- a novel nanotechnology- based system |
| Funding Source: | Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) |
| Role: | Co-PI |
| Date: | 2019 - 2020 |
| Title: | A phase 1 dose-escalation study of ATR Inhibitor M6620 in combination with pre-operative chemoradiotherapy for the treatment of locally-advanced esophageal adenocarcinoma |
| Funding Source: | Holden Care Center |
| Role: | Co-PI |
| Date: | 2018 - 2023 |
| Title: | A phase 2 clinical trial of high dose ascorbate for pancreatic cancer and lung cancer |
| Funding Source: | National Cancer Institute |
| Role: | Medical Monitor |
| Date: | 2018 - 2022 |
| Title: | Clinical Core C |
| Funding Source: | NIH NCI Neuroendocrine SPORE |
| Role: | Member |
Selected Publications
Peer-Reviewed Articles
- Grewal, US, Fei, N, Chandrasekharan, C, Bellizzi, AM, Sethi, S, Gosse, M. Neuroendocrine Tumor-Associated Chromogranin A Tubulopathy. Am J Med 138(6):e109-e110, 2025. e-Pub 2025. PMID: 39732152.
- Borbon, LC, Sherman, SK, Breheny, P, Chandrasekharan, C, Menda, Y, Bushnell, DL, Bellizzi, AM, Ear, PH, O'Dorisio, MS, O’dorisio, T, Dillon, JS, Howe, JR. Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. Ann Surg Oncol 32(2):1136-1148, 2025. e-Pub 2025. PMID: 39505730.
- Bodeker, KL, Smith, BJ, Berg, D, Chandrasekharan, C, Sharif, S, Fei, N, Vollstedt, S, Brown, H, Chandler, M, Lorack, A, McMichael, S, Wulfekuhle, J, Wagner, BA, Buettner, GR, Allen, BG, Caster, JM, Dion, B, Kamgar, M, Buatti, JM, Cullen, JJ. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol 77, 2024. e-Pub 2024. PMID: 39369582.
- Grewal, US, Loeffler, BT, Paschke, A, Dillon, JS, Chandrasekharan, C. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. J Gastrointest Cancer 55(3):1165-1170, 2024. e-Pub 2024. PMID: 38780680.
- Mouser, B, Howe, JR, Atari, O, Dillon, JS, Chandrasekharan, C, Parekh, KR, Bashir, MA. Screening for Carcinoid Heart Disease: Trends and Future Perspectives. Int J Cardiol Cardiovasc Risk Prev 22, 2024. e-Pub 2024. PMID: 38911359.
- Poellmann, MJ, Bu, J, Liu, S, Wang, AZ, Seyedin, SN, Chandrasekharan, C, Hong, H, Kim, YS, Caster, JM, Hong, S. Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients. Biosens Bioelectron 226, 2023. e-Pub 2023. PMID: 36753988.
- Ziogas, IA, Tasoudis, PT, Borbon, LC, Sherman, SK, Breheny, P, Chandrasekharan, C, Dillon, JS, Bellizzi, AM, Howe, JR. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms. Ann Surg Oncol 30(1):148-160, 2023. e-Pub 2023. PMID: 36227392.
- Borbon, LC, Tran, CG, Sherman, SK, Ear, PH, Chandrasekharan, C, Bellizzi, AM, Dillon, JS, O’dorisio, T, Howe, JR. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?. Ann Surg Oncol 29(11):6936-6946, 2022. e-Pub 2022. PMID: 35802214.
- Tran, CG, Sherman, SK, Suraju, M, Nayyar, A, Gerke, H, Abiad, RG, Chandrasekharan, C, Ear, PH, O’dorisio, T, Dillon, JS, Bellizzi, AM, Howe, JR. Management of Duodenal Neuroendocrine Tumors. Ann Surg Oncol 29(1):75-84, 2022. e-Pub 2022. PMID: 34515889.
- Tran CG, Sherman SK, Scott AT, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 28(2):732-741, 2021. e-Pub 2021. PMID: 32656719.
- Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res 26(8):2011-2021, 2020. e-Pub 2020.
- Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 29(2):293-316, 2020. e-Pub 2020. PMID: 32151362.
- Shahjehan F, Kamatham S, Chandrasekharan C, Kasi PM. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. Drugs Today (Barc) 55(11):683-693, 2019. e-Pub 2019. PMID: 31840683.
- Dillon JS, Chandrasekharan C. Telotristat Ethyl: A Novel Agent for the Therapy of Carcinoid Syndrome Diarrhea. Future Oncol 14(12):1155-1164, 2018. e-Pub 2018. PMID: 29350062.
- Wehmeier KR, Kurban W, Chandrasekharan C, Onstead-Haas L, Mooradian AD, Haas MJ. Inhibition of ABCA1 Protein Expression and Cholesterol Efflux by TNF α in MLO-Y4 Osteocytes. Calcif Tissue Int 98(6):586-595, 2016. e-Pub 2016. PMID: 26759003.
- Peddi P, Gallagher KM, Chandrasekharan C, Wang Q, Gonzalez-Toledo E, Nair BS, Munker R, Mills GM, Koshy NV. Tolosa-hunt syndrome in double-hit lymphoma. Case Rep Oncol Med, 2015. e-Pub 2015. PMID: 25918657.
- Chithra P, Chandrikha C, Kannan AS, Srinath S, Srinivasan V, Jayanthi V. Clinical and life style variables in functional dyspepsia and its sub-types. Trop Gastroenterol 33(1):33-38, 2012. e-Pub 2012. PMID: 22803293.
Review Articles
- Tran, CG, Sherman, SK, Chandrasekharan, C, Howe, JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Hematol Oncol Clin North Am 39(1):37-53, 2025. e-Pub 2025. PMID: 39510676.
- Halfdanarson, TR, Mallak, N, Paulson, S, Chandrasekharan, C, Natwa, M, Kendi, AT, Kennecke, HF. Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835530.
- Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 13(20):5117, 2021. e-Pub 2021. PMID: 34680266.
Other Articles
- Perez K, Rivero JD, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract, 2025.
- Howe JR, Menda Y, Chandrasekharan C, Bellizzi AM, Quelle DE, O'Dorisio M, Dillon JS The University of Iowa Neuroendocrine Tumor Clinic. Endocr Pract 31(1):4-18, 2025. PMID: 39349242.
- Ziogas, IA, Dillon, JS, Chandrasekharan, C, Howe, JR ASO Author Reflections. Ann Surg Oncol 30(1):161-162, 2023. PMID: 36209329.
Abstracts
- Grewal US, Patel R, Loeffler BT, Rathjens S, Abdilleh K, Zelada F, Brown TJ, Fei N, Sharif S, Chandrasekharan C. Germline genetic testing among patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
- Grewal U, Patel R, Loeffler B, Rathjens S, Abdilleh K, Zelada F, Rosenzweig A, Chandrasekharan C. Clinical trial access in patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
- Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Menda Y, Bushnell D, Bellizzi AM, Ear P, O’Dorisio M, O’Dorisio TM, Dillon JS, BCh, Howe JR. Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. 2023 SSO Annual Meeting, 2024. e-Pub 2024. PMID: 39505730.
- Grewal US, Loeffler BT, Paschke A, Dillon JS, Chandrasekharan C. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience. 2023 NANETS Annual Symposium, 2024. e-Pub 2024. PMID: 38780680.
- Tran CG, Borbon LC, Tow DH, Shilyansky J, Li G, Egan J, Sherman SK, Abusada E, Tang J, Govindan R, Fields RC, Braun TA, Chan CH, Chandrasekharan C, Spitz D, Quelle DE, Bellizzi AM, Howe JR, Ear PH. A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
- Chang KC, Berg D, Chandrasekharan C, Steckly K, Sharif S, Chan CH. Circulating tumor DNA for predicting peritoneal only disease recurrence in colon cancer. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Grewal US, Aggarwal M, Kumar P, Fei N, Monga V, Chandrasekharan C. Association of lifestyle-related risk factors with incidence and mortality rates of colorectal cancer among adolescents and young adults (AYA) in the United States. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
- Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu T, Graham RP, Markovic S, Dong H, Yoon HH. Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA). 2020 ASCO Annual Meeting, 2020. e-Pub 2020.
- Marcondes Westin GF, Alsidawi S, Chandrasekharan C, Briggler AM, Huffman B, Pallante A, Hubbard JM, Alberts SR, Halfdanarson TR. Outcomes of second line treatment in patients with advanced and metastatic biliary cancers. 2017 GI ASCO Annual Meeting.
- Kaemmer C, Umesalma S, Maharjan C, Kohlmeyer J, Lingo J, Wilkerson E, Sheehy R, Leidinger M, Meyerholz D, Bell S, Zamba G, Breheny P, Lattime E, Chandrasekharan C, Bellizzi A, Herring L, Graves L, Darbro B, Yuan Z, Libutti S, Quelle D. Therapies targeting CDK4/6 cause regression, immune cell activation, and sensitization to PD-L1 immunotherapy in pancreatic neuroendocrine tumors. 2023 NANETS Annual Symposium.
- Chandrikha C, Chithra P, Kannan A. Prevalence and subtypes of functional dyspepsia using ROME III criteria: do we need to add more?. 2008 Asia Pacific Digestive Week.
- Chandrasekharan C, Relan M, Shuja S, Yeckley S. Giant Adrenal Myelolipoma – rare tumor with increasing incidence. 12th Annual Southern Hospital Medicine Conference.
- Anand K, Seth A, Chandrasekharan C, Blondin J. Bullous pemphigoid as presenting feature of angioimmunoblastic T cell lymphoma. ACP.
- Nepalli A, Patel A, Chandrasekharan C. Biclonal Gammapathy of significance -remission following autologous stem cell transplant. 2015 AFMR Southern Regional Meeting.
- Ghobrial S, Dillon JS, O’Dorisio TM, Bellizzi AM, Chandrasekharan C, Howe JR, Mott S, Zamba G, O’Dorisio SM, Menda Y. Prospective Evaluation of the Impact of Ga-68 DOTATOC PET/CT on Clinical Management of Neuroendocrine Tumors (NETs). 2019 SNMMI Annual Meeting.
- Tow DH, Ridder M, Tran CG, Borbon LC, Li G, Kaemmer CA, Abusada E, Mahalingam AH, Sadanandam A, Chandrasekharan C, Dillon J, Spitz DR, Quelle DE, Chan CH, Bellizzi A, Howe JR, Ear PH. Investigating serotonin metabolism in neuroendocrine cancers. 2023 NANETS Annual Symposium.
- Amjad US, Kaemmer C, Chandra M, Kohlmeyer J, G D, W S, Sheehy R, Mr L, Meyerholz D, Zamba G, O'Dorisio S, Dillon J, Scott A, Hein EP, Howe J, Chandrasekharan C, Bellizzi A, Herring L, Graves L, Darbro B, Quelle D. Efficacy of Combined MEK and CDK Targeted Therapies for Pancreatic Neuroendocrine Tumors. 2020 NANETS Annual Symposium.
- Ear PH, Tran C, Li G, Egan J, Lotenschtein C, Abusada E, Mudd J, Kaemmer C, AMiller, Chan C, Chandrasekharan C, Wu M, O'Dorisio S, Quelle D, Bellizzi A, RCFields, Howe J. A Systematic Workflow to Identify Anti-cancer Drugs Targeting Small Bowel Neuroendocrine Tumors and Neuroendocrine Carcinomas. 2020 NANETS Annual Symposium.
- Chau J, Yu N, Bakeri H, Menda Y, Dillon JS, Chandrasekharan C. Real world analysis of peptide receptor radionucleotide therapy (PRRT) in the treatment of neuroendocrine tumors. 2020 ASCO Annual Meeting.
- Bodeker K, Bushnell D, Madsen M, Menda Y, Gaimari-Varner K, Graves S, O'Dorisio T, Dillon J, Chandrasekharan C. 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Personalized Therapy of Selected Patients with Midgut Neuroendocrine Tumors: A First-In-Man Clinical Trial. 2019 NANETS Annual Symposium.
- Abushahin L, Monga V, Berg D, Chandrasekharan C, Tanas M, Henry M, Mckay M, Mott S, Milhem M. Phase 1b study of Decitabine in combination with Gemcitabine in treatment of refractory pancreatic adenocarcinoma and advanced soft tissue or bone sarcomas. 2018 AACR Annual Meeting.
- Grewal US, Manchkanti S, Fei N, Chandrasekharan C. Treatment patterns and outcomes in patients with early onset cholangiocarcinoma: A large database analysis. 2024 ASCO Annual Meeting.
- Tow DH, Ridder M, Tran CG, Borbon LC, Li G, Kaemmer CA, Abusada E, Mahalingam AH, Sadanandam A, Chandrasekharan C, Dillon J, Spitz DR, Quelle DE, Chan CH, Bellizzi A, Howe JR, Ear PH. Investigating Serotonin Metabolism in Neuroendocrine Cancers. 2023 NANETS Annual Symposium.
- Grewal US, Gandhi N, Soares H, Demeure MJ, Del Rivero J, Chandrasekharan C, Xiu J, Lou E. Characterization of the Genomic and Immune Landscapes of 88 Cases of Pheochromocytomas and Paragangliomas: Implications for Development of Targeted Therapeutics. 2024 NANETS Annual Symposium.
- Grewal US, Patel R, Semprini J, O'Rorke M, Dillon JS, Chandrasekharan C. Comparative analysis of characteristics of outcomes of early age onset vs average age onset small bowel neuroendocrine tumors. 2024 NANETS Annual Symposium.
- Ahnert JR, Sepulveda Sanchez JM, Alese OB, Anguera G, Chandrasekharan C, Chawla SP, Burgess MA, Abdelrahim M, Villano JL, Zhang B, Wang Y, Yu X, Zhong Z, Luo X, Fan S, Shi M, Su W, Villar MV. Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma. 2025 ASCO Annual Meeting.
Patient Reviews
CV information above last modified July 22, 2026